Use of incretin-based therapies in women using hormone replacement therapy (HRT)

Abstract

Keywords

MHT HRT incretin-based therapy GLP-1 agonists menopause

Get full access to this article

View all access options for this article.

References

Jaacks

Vandevijvere

Pan

, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol 2019; 7(3): 231–240.

Global BMI Mortality Collaboration Di Angelantonio

Bhupathiraju

et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016; 388(10046): 776–786.

Abdelaal

le Roux

Docherty

. Morbidity and mortality associated with obesity. Ann Transl Med 2017; 5(7): 161.

Marlatt

Pitynski-Miller

Gavin

, et al. Body composition and cardiometabolic health across the menopause transition. Obesity 2022; 30(1): 14–27.

Rubino

Cummings

Eckel

, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025; 13: 221–262.

Lopez-Jimenez

Almahmeed

Bays

, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022; 29(17): 2218–2237.

Stefan

Schulze

. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol 2023; 11(6): 426–440.

Crosbie

Kitson

McAlpine

, et al. Endometrial cancer. Lancet 2022; 399(10333): 1412–1428.

Barr

Ryan

NAJ

Derbyshire

, et al. Weight loss during intrauterine progestin treatment for obesity-associated atypical hyperplasia and early-stage cancer of the endometrium. Cancer Prev Res 2021; 14(11): 1041–1050.

10.

GBD 2021 Diabetes Collaborators . Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023; 402(10397): 203–234.

11.

International Diabetes Federation . Diabetes is “a pandemic of unprecedented magnitude” now affecting one in 10 adults worldwide. Diabetes Res Clin Pract 2021; 181: 109133. DOI: 10.1016/j.diabres.2021.109133.

12.

Wang

Yang

, et al. Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews. Endocrine 2025; 16: 04179.

13.

Jastreboff

le Roux

Stefanski

, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2024; 392: 958–971.

14.

Karagiannis

Malandris

Avgerinos

, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia 2024; 67(7): 1206–1222.

15.

Deanfield

Verma

Scirica

, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024; 404(10454): 773–786.

16.

Packer

Zile

Kramer

, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025; 392(5): 427–437. DOI: 10.1056/NEJMoa2410027.

17.

Syed

Adam

Miller

, et al. Obesity management for patients with coronary artery disease and heart failure. Heart Fail Clin 2025; 21: 257–271.

18.

National Institute for Health and Care Excellence . Semaglutide for managing overweight and obesity. London: NICE, 2023. https://www.nice.org.uk/guidance/ta875.

19.

National Institute for Health and Care Excellence . Tirzepatide for managing overweight and obesity. London: NICE, 2024. https://www.nice.org.uk/guidance/ta1026.

20.

Rovinski

Ramos

Fighera

, et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res 2018; 168: 83–95.

21.

Mukherjee

Davis

. Update on menopause hormone therapy; current indications and unanswered questions. Clin Endocrinol (Oxf) 2025. DOI:10.1111/cen.15211.

22.

Kapkayeva

Ginzburg

. Possible drug interaction between GLP-1 agonist and oral contraceptives. Reproductive health access project, 2025. https://www.reproductiveaccess.org/resource/possible-drug-interaction-between-glp-1-agonist-and-oral-contraceptives/.

23.

Kapitza

Nosek

Jensen

, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 2015; 55(5): 497–504.

24.

Jordy

Breitschaft

Christiansen

, et al. Oral semaglutide does not affect the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel. Diabetes 2018; 67(Supplement_1): 1135.

25.

Mounjaro^® KwikPen^® Summary of Product Characteristics.

Toronto, Ontario: Eli Lilly and Company Limited, 2024. https://www.medicines.org.uk/emc/product/15481/smpc.

26.

Zentiva

UK.

Progesterone 100 mg Capsules, soft [summary of product characteristics]. Zentiva. 2024. https://www.medicines.org.uk/emc/product/15401/smpc#gref.

27.

Ettinger

Klein

. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 1998; 69(5): 865–869.

28.

Manley

Hillard

Clark

et al. Management of unscheduled bleeding on HRT: a joint guideline on behalf of the British Menopause Society, Royal College Obstetricians and Gynaecologists, British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Faculty of Sexual and Reproductive Health, Royal College of General Practitioners and Getting it Right First Time. Post Reprod Health 2024; 30(2): 95–116. DOI: 10.1177/20533691241254413.